Chimeric Antigen Receptor (CAR) T cells are among the most promising cancer therapeutics of the past decade. However, immunogenic components, often of murine origin, can elicit anti-CAR immune responses that limit their persistence and efficacy. “Humanization” replaces murine sequences with human counterparts, reducing immunogenicity while preserving function. This article discusses mechanisms of CAR T cell rejection and the clinical potential of humanized CAR designs.
| Journal | BIOspektrum |
|---|---|
| Publisher | Springer |
| Publication Date | 2026-03-01 |
| Publication Year | 2026 |
| Volume | 32 |
| Issue | 2 |
| Pages | 167-169 |
| Document Type | Journal Article |
| Print ISSN | 0947-0867 |
| eISSN | 1868-6249 |
| DOI | 10.1007/s12268-026-2706-y |
| NARA Access Coverage | 2011-01-01~Current |
|---|---|
| Journal Homepage | https://www.springer.com/journal/12268 |
| Publisher Page | Open Publisher Page |